BIOTECHNOLOGY IN CANCER IMMUNOTHERAPY: EMERGING APPROACHES AND CLINICAL TRIALS

Abstract

The integration of biotechnology into cancer immunotherapy has transformed the therapeutic landscape of oncology, offering novel mechanisms for enhancing immune-mediated tumor eradication. This research provides a comprehensive analysis of three principal immunotherapeutic strategies immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR) T-cell therapy, and monoclonal antibodies (mAbs)—with emphasis on their clinical efficacy, mechanistic innovation, and biomarker-guided personalization. Utilizing data from recent clinical trials and biotechnology-enabled treatment protocols, the study reveals that PD-1 inhibitors exhibit superior response rates in melanoma and non-small cell lung cancer, while CAR T-cell therapy achieves the highest remission rates in hematologic malignancies, albeit with elevated risks of cytokine release syndrome. Monoclonal antibodies demonstrate consistent performance across HER2-positive and CD20-positive cancers, with emerging bispecific variants enhancing tumor–immune engagement. Quantitative results showed response rates of up to 80% in melanoma (PD-1), long-term remission exceeding 65% in CAR T-treated leukemia patients, and manageable toxicity profiles with advanced mAb constructs. Additionally, biomarker analysis confirmed that high PD-L1 expression and tumor mutational burden (TMB) significantly predict positive therapeutic outcomes. Twelve multi-type visualizations and nine structured tables support the comparative performance and safety profiles across modalities. The findings underscore the pivotal role of biotechnology in enabling personalized immunotherapy and optimizing patient selection. Conclusively, the study highlights that while immunotherapy has redefined cancer treatment paradigms, further innovation is needed to address resistance mechanisms and broaden efficacy in solid tumors. Future strategies integrating artificial intelligence, multi-omics biomarkers, and combination regimens may bridge these gaps, heralding a new era of precision oncology.